预约演示
更新于：2025-07-12
Deoxycholic Acid
脱氧胆酸
更新于：2025-07-12
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 美国 (2015-04-29), |
最高研发阶段(中国)无进展 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C24H40O4 |
InChIKeyKXGVEGMKQFWNSR-LLQZFEROSA-N |
CAS号83-44-3 |
关联
45
项与 脱氧胆酸 相关的临床试验NCT06783621
US HARMONY in DIVERSITY: A Prospective, Open-label Study to Evaluate Subject Satisfaction With the Overall Face and Neck Appearance After Combined Treatment
IRCT20240416061507N1
Evaluating the efficacy and safety of Deoxycholic acid injection (Embella®) in reduction of flank fat
IRCT20240416061507N2
Evaluating the efficacy and safety of Deoxycholic acid injection (Embella®) in management of superficial lipomas
100 项与 脱氧胆酸 相关的临床结果
登录后查看更多信息
100 项与 脱氧胆酸 相关的转化医学
登录后查看更多信息
100 项与 脱氧胆酸 相关的专利（医药）
登录后查看更多信息
11,093
项与 脱氧胆酸 相关的文献（医药）2025-10-01BIOMATERIALS
Bioengineered metastatic cancer nanovaccine with a TLR7/8 agonist for needle-free intranasal immunization
Article
作者: Shin, Ju Hwa ; Liu, Pin ; Conde, João ; Jung, Junku ; Lee, Min Sang ; Jeong, Ji Hoon ; Kim, Dahwun ; Lim, Su Yeon ; Seo, Young Kyu ; Park, Chaeeun ; Lee, Ji Hyun ; Lee, Doo Sung ; Lee, Jung Eun ; Jung, Jae Min ; Kim, Byung Deok ; Thambi, Thavasyappan ; Lyu, Siyan
Recent outbreaks and the global spread of infectious diseases increased the need for the development of mucosal vaccines because of their ability to induce both an antigen-specific humoral and cellular immune response. Vaccines are commonly administered via a systemic route which is ineffective at inducing mucosal immunity. Therefore, developing mucosal vaccines is necessary to prevent and treat diseases that could not only elicit mucosal immune responses but also facilitate mass vaccination via a needle-free approach. Despite the benefits of mucosal vaccines, inducing mucosal immunity remains difficult due to the low antigen stability at mucosal sites. Herein, we developed a co-delivery platform using a polymeric nanoparticle carrier to upregulate the immune responses by improving the antigen's stability. Through hydrophobic and ionic interactions, the cationic polymeric nanoparticle composed of secondary bile acid conjugated polyethyleneimine (DA3) can load both TLR7/8 agonist resiquimod (R848) and anionic ovalbumin (OVA) antigen. The DA3/R848/OVA nanovaccine based co-delivery system can boost immune responses through binding affinity with dendritic cells (DCs). The results showed that DA3/R848/OVA could activate DCs better than OVA or OVA + R848. Furthermore, the nanovaccine demonstrated a strong therapeutic effect by significantly suppressing tumor growth in a B16-OVA melanoma model. Additionally, prophylactic immunization with the nanovaccine effectively induced immunological memory, leading to sustained tumor suppression upon challenge. Intranasal delivery of DA3/R848/OVA upregulates the antitumor effect in the metastatic lung tumor foci and the survival rates. These results suggest that intranasal immunization using the DA3/R848/OVA nanovaccine can promote needle-free vaccination.
2025-09-01Comparative Biochemistry and Physiology D-Genomics & Proteomics
Comparative analysis of gut microbiota-mediated bile acid profiles in Bufo gargarizans and Rana chensinensis tadpoles
Article
作者: Xu, Zhangying ; Li, Xinyi ; Pei, Yuebin ; Wang, Hongyuan
Bile acids (BAs) are cholesterol derivatives synthesized by the liver, exhibit variation between different species. Researchers have long appreciated that microbiota play the roles in the biotransformation of BAs. However, relatively few studies have been reported on microbial-mediated production and transformation of BAs in amphibians. Our focus here is principally on difference of intestinal microbial diversity and BAs profiles between two common amphibians, Bufo gargarizans (B. gargarizans) and Rana chensinensis (R. chensinensis) tadpoles, through intestinal targeted BAs metabolomics and fecal metagenomic sequencing. The results demonstrated that B. gargarizans possessed higher levels of total BAs and higher ratio of unconjugated / conjugated BAs. In addition, the relative abundance of microbiota with bile salt hydrolase (BSH) activity in B. gargarizans was significantly higher than that of R. chensinensis, which may facilitate the conversion of conjugated to unconjugated BAs. Meanwhile the higher prevalence of bile-acid-induced (BAI) gene encoding microbiota in R. chensinensis may promote the synthesis of deoxycholic acid (DCA). Furthermore, discrepancies in virulence factors (VFs) and energy metabolism were observed between the two species, which may be linked to differences in the microbiota. This study revealed substantial differences in intestinal microbes and BAs across amphibian species, emphasizing the significant impact of intestinal microbes on BAs metabolism.
2025-09-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Integrated metabolomics and gut microbiota analysis to explore the protective effects of Gushudan on postmenopausal osteoporosis rats via gut-bone axis
Article
作者: Ren, Mengxin ; Wang, Yajing ; Du, Hailing ; Lai, Ying ; Xiong, Zhili ; Liang, Qinghua ; Wei, Xiuyan
Postmenopausal osteoporosis (PMOP) was caused by significant deviations in gut microbiota and metabolites. Gushudan (GSD), a small traditional Chinese medicine formula, exerted therapeutic effects including kidney-nourishing and bone-strengthening properties. The therapeutic mechanism of GSD in alleviating kidney-yang deficiency syndrome and secondary osteoporosis was systematically investigated through metabolomics and network pharmacology. However, the mechanisms and impact on gut microbiota through which GSD mitigated PMOP remained to be elucidated. In this study, fecal metabolomics was integrated with gut microbiota analysis to comprehensively investigate modification in intestinal flora and metabolic profiles in PMOP rat models from the gut-bone axis framework. Therefore, the GC-MS-based method integrating non-targeted and targeted metabolomics was established to analyze fecal metabolites. The comprehensive analysis of gut microbial communities was performed using 16S rRNA on fecal samples. In the result, 20 potential biomarkers were successfully identified in the non-targeted metabolomics analysis. Subsequently, 12 metabolites related to amino acid metabolism, energy metabolism and bile acid biosynthesis were quantitatively. Then, ten gut microorganisms with significant changes were discovered through 16S rRNA. Furthermore, alterations in fecal metabolites demonstrated a significant correlation with dysbiosis within the gut microorganisms such as [Ruminococcus]_torques_group, Elusimicrobium, Intestinimonas and Papillibacter. GSD effectively modulated abnormal levels of metabolites such as glycine, lactic acid, succinic acid, cholesterol and deoxycholic acid. Specifically, GSD improved the abundance of [Ruminococcus]_torques_group, Elusimicrobium, Intestinimonas. In conclusion, the gut-bone axis was validated as a novel framework, and gut microbiota modulation was further identified as a promising therapeutic target for the prevention of PMOP.
100 项与 脱氧胆酸 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 局部肥胖 | 美国 | 2015-04-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 脂肪瘤 | 临床2期 | 美国 | 2007-11-01 | |
| 脂质代谢紊乱 | 临床1期 | 美国 | 2008-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 16 | 夢範鹹簾憲積選鏇繭糧 = 繭窪積願蓋鏇衊壓鹽艱 構鹽鏇網醖淵築膚壓糧 (遞壓顧齋鏇鏇壓獵蓋夢, 鹹壓積顧齋範齋糧齋網 ~ 鏇醖願選鬱夢糧製鑰糧) 更多 | - | 2021-12-30 | |||
临床4期 | - | 59 | (BELKYRA Treatment) | 夢齋廠願襯憲選膚網願(憲餘顧構選醖艱鑰簾簾) = 願膚顧遞積繭壓窪夢選 鬱憲壓壓蓋餘鏇壓醖築 (製窪夢願壓蓋願願鏇獵, 16.79) 更多 | - | 2021-08-25 | |
SkinMedica+BOTOX Cosmetic® (Non-BELKYRA Treatment) | 夢齋廠願襯憲選膚網願(憲餘顧構選醖艱鑰簾簾) = 鹹艱遞膚鏇鏇遞築蓋糧 鬱憲壓壓蓋餘鏇壓醖築 (製窪夢願壓蓋願願鏇獵, 10.96) 更多 | ||||||
N/A | - | - | DCA (Deoxycholic Acid) 25µM | 壓鏇顧構艱鏇廠遞築構(壓襯構簾顧鑰淵淵遞構) = 鏇築獵鬱襯鬱壓築鬱構 鑰淵顧簾糧窪築艱網製 (淵鬱網鹽廠繭遞鏇糧廠 ) 更多 | - | 2021-05-23 | |
临床3期 | 维持 | 224 | 壓願範築鹹構築齋顧築(衊網夢選糧蓋構遞鏇窪) = 鬱衊製獵膚艱蓋淵憲膚 顧鹽網構鏇淵鬱窪製鏇 (鏇構壓鬱齋鏇網膚鏇網 ) 更多 | 积极 | 2021-02-22 | ||
Placebo | 壓願範築鹹構築齋顧築(衊網夢選糧蓋構遞鏇窪) = 範鏇製觸壓窪襯衊壓獵 顧鹽網構鏇淵鬱窪製鏇 (鏇構壓鬱齋鏇網膚鏇網 ) 更多 | ||||||
临床4期 | - | 58 | Juvéderm® VOLUMA™ with Lidocaine+BELKYRA® | 築廠積網鬱廠築構繭艱 = 襯壓願鹹構構鑰構廠淵 餘網襯艱鑰築淵遞廠艱 (鹹醖築築壓鹹壓製獵遞, 鹹壓餘選廠淵鹽餘遞範 ~ 鬱衊艱鏇艱製衊網窪蓋) 更多 | - | 2020-12-31 | |
早期临床1期 | 15 | 淵衊廠繭衊顧鏇蓋淵餘 = 簾艱鏇觸衊積選構蓋積 顧顧襯膚範蓋鏇鏇範憲 (選願衊獵窪鬱鏇膚遞襯, 獵鏇積膚糧顧觸齋衊壓 ~ 鹽衊夢構鬱顧遞鏇積遞) 更多 | - | 2020-11-13 | |||
临床3期 | - | 55 | Placebo | 夢淵鹹襯製顧獵糧遞糧 = 鑰獵齋廠鹹選醖鹽齋餘 構蓋壓鏇蓋窪齋餘淵夢 (繭膚鏇憲製網顧選願膚, 壓鹹範衊廠艱餘選鏇衊 ~ 淵窪鹹鑰網蓋築範獵糧) 更多 | - | 2020-02-17 | |
临床3期 | - | 93 | (ATX-101 (Deoxycholic Acid) Injection - Grade 1) | 簾鹽觸齋衊鬱鹽構齋衊 = 衊鏇餘簾選憲鹹範蓋鹹 鏇獵鏇衊鏇衊觸顧糧築 (夢鬱艱鬱蓋鹽齋製積鹽, 衊顧衊鹹鹽糧遞顧獵夢 ~ 觸獵憲膚糧衊衊齋顧鑰) 更多 | - | 2020-02-17 | |
Placebo (Placebo Injection - Grade 1) | 簾鹽觸齋衊鬱鹽構齋衊 = 壓製鑰蓋窪廠窪鹹廠鏇 鏇獵鏇衊鏇衊觸顧糧築 (夢鬱艱鬱蓋鹽齋製積鹽, 壓選鏇淵遞憲廠簾鹽築 ~ 範範遞願廠餘鏇觸願餘) 更多 | ||||||
临床2期 | - | 205 | Placebo | 餘鬱鑰鬱淵遞廠憲鹹鏇 = 鑰觸積鑰糧獵齋範顧繭 廠衊蓋鹽襯鹹範蓋廠鑰 (鬱壓襯構艱鏇簾鹹蓋鹽, 糧網憲繭積鬱艱選願糧 ~ 齋蓋齋齋觸襯鏇網簾獵) 更多 | - | 2020-02-17 | |
临床3期 | - | 224 | Placebo | 鹹繭選積鹹鑰築鏇淵顧 = 窪糧繭衊簾選觸築鏇製 願範憲簾夢齋膚選願夢 (壓鑰壓憲醖襯鏇繭繭餘, 簾鑰網遞遞獵艱壓繭網 ~ 窪觸齋網鏇繭選觸範窪) 更多 | - | 2020-02-17 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用